Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
San Raffaele University
Fudan University
St. Jude Children's Research Hospital
Novartis
GlaxoSmithKline
UNICANCER
ImmunityBio, Inc.